8-K: Precipio Reports Strong 2025 Revenue Growth, Positive EBITDA

Precipio, Inc. announced preliminary unaudited financials for Q4 and fiscal year 2025, reporting significant revenue growth and a shift to positive Adjusted EBITDA and operating cash flow.

Summary

• Precipio's revenues increased 30% year-over-year to $24.0M in 2025, up from $18.5M in 2024.
• Q4-2025 revenues were $6.7M, marking a 23% increase year-over-year from $5.4M in Q4-2024.
• Adjusted EBITDA for Q4-2025 was $0.95M, a significant improvement from $0.40M in Q4-2024.
• Full-year 2025 Adjusted EBITDA reached $1.23M, compared to a ($1.5M) loss in 2024.
• The company generated $368K of positive operating cash flow during Q4-2025, contributing to a total of $688K for the full year 2025.
• Excluding unusual items, adjusted operating cash flow was $617K for Q4-2025 and $727K for 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive announcement, reflecting strong financial performance with significant revenue growth and a crucial shift to profitability and positive cash flow, indicating improved operational efficiency and financial health.

Positives

• Achieved 30% year-over-year revenue growth in 2025, reaching $24.0M.
• Reported 23% year-over-year revenue growth in Q4-2025, with revenues of $6.7M.
• Successfully transitioned to positive Adjusted EBITDA for Q4-2025 ($0.95M) and the full year 2025 ($1.23M), a substantial improvement from a negative EBITDA in 2024.
• Generated positive operating cash flow of $368K in Q4-2025 and $688K for the full year 2025.
• Adjusted operating cash flow (excluding unusual items) was $617K for Q4-2025 and $727K for 2025, demonstrating underlying financial strength.
• The shift to positive EBITDA and cash flow enables investment in longer-term growth projects, moving away from a constant focus on short-term cash burn.
• Shareholder value tripled in 2025, indicating strong market confidence and performance.

Negatives

• The financial results are preliminary and unaudited, meaning they are subject to potential adjustments upon final audit.
• Operating cash flow figures include certain unusual items related to Change Healthcare transactions and COVID-related Employee Retention Credit, though adjusted figures are also provided.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause actual results, performance, or achievements to be materially different from any future results expressed or implied.
• Important factors discussed under the caption 'Risk Factors' in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other reports filed with the U.S. Securities and Exchange Commission, could impact future performance.

Future Outlook

The company is confident in its ability to continue creating shareholder value and plans to invest in longer-term growth projects, shifting focus from short-term cash burn. Additional information and a more in-depth discussion on 2025 performance and 2026 prospects will be provided in a shareholder call in early April, following the 10-K filing.

Management Comments

• "Becoming an EBITDA and cash-flow positive business has a very important impact on how we manage the business. It allows us to now invest in growth projects that consider a longer-term perspective for the Company, rather than a constant focus on short-term cash burn considerations." Ilan Danieli, CEO.
• "2025 was a great year for us, one where the business performed well, and shareholders saw their value triple. We are confident in our ability to continue to create this value." Ilan Danieli, CEO.

Industry Context

StockSavvy.ai notes that Precipio's strong revenue growth and transition to positive Adjusted EBITDA and operating cash flow are significant achievements in the competitive cancer diagnostics sector. This financial turnaround positions the company to potentially increase its market share and invest further in its proprietary diagnostic products and services, which aim to address cancer misdiagnoses and improve patient outcomes, aligning with broader industry trends towards precision medicine and improved diagnostic accuracy.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks or competitors. StockSavvy.ai would typically compare Precipio's 30% revenue growth and shift to profitability against similar-sized biotechnology or cancer diagnostics companies, evaluating their growth rates, EBITDA margins, and cash flow generation to assess relative performance and market positioning.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to improved financial performance, profitability, and positive cash flow. The CEO noted shareholder value tripled in 2025.
• Employees: A more financially stable company may offer better job security and opportunities for growth, as the company can now invest in longer-term projects.
• Customers: Continued investment in diagnostic products and services aims to deliver higher accuracy and improved patient outcomes.
• Creditors: Improved financial health, positive EBITDA, and cash flow reduce financial risk, potentially making the company a more attractive borrower.

Next Steps

• Filing of the Company's 10-K report.
• Shareholder call in early April [2026] to provide additional information and a more in-depth discussion on 2025 performance and 2026 prospects.

Key Dates

Recommendation

The company has demonstrated a significant financial turnaround, achieving 30% revenue growth, shifting from negative to positive Adjusted EBITDA, and generating positive operating cash flow. This indicates strong operational execution and improved financial health, positioning Precipio for sustained growth and value creation. The ability to invest in long-term projects rather than focusing on cash burn is a critical positive development for future prospects.

Keywords

cancer diagnostics, biotechnology, healthcare, revenue growth, EBITDA, cash flow, financial results, PRPO, SEC filing, Q4 2025, FY 2025